Phase Ib Trial Shows 40 Percent of Patients Receiving Keytruda Alive After 36-Month Follow Up June 02, 2016Vol.- No.-
Drugs & Targets FDA Grants Approvals to Tecentriq, Opdivo, Imbruvica, Lenvima June 02, 2016Vol.- No.-
Cancers Originating on Left Side of Colon Associated with Longer Survival, Study Says June 02, 2016Vol.- No.-
Drugs & Targets ProNAi Therapeutics and Carna Biosciences to commercialize AS-141 May 27, 2016Vol.42 No.21
Drugs & Targets CHMP Issues Positive Opinion For Kyprolis in Multiple Myeloma May 27, 2016Vol.42 No.21
In Brief Lightpoint Medical signs agreement for Beta Emission Tomography technology from University of Arizona researchers May 27, 2016Vol.42 No.21
In Brief University of Chicago and Blue Cross and Blue Shield launch oncology medical home May 27, 2016Vol.42 No.21
